High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: What is the best timing for stool sampling?

Inflammatory Bowel Diseases

Volumn 21, Issue 5, 2015, Pages 1072-1076

  Calafat, Margalida ^a,b   Cabré, Eduard ^a   Mañosa, Míriam ^a   Lobatón, Triana ^a   Marín, Laura ^a   Domènech, Eugeni ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

fecal calprotectin; stool sampling; ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; CALGRANULIN; CORTICOSTEROID; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL MARKER;

ADULT; ARTICLE; CHRONOLOGY; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE EXACERBATION; FECES ANALYSIS; FECES LEVEL; FEMALE; HOSPITAL ADMISSION; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ULCERATIVE COLITIS; CHEMISTRY; COLITIS, ULCERATIVE; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FOLLOW UP; METABOLISM; PROGNOSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME;

BIOMARKERS; COLITIS, ULCERATIVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84929094365     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000349     Document Type: Article

References (27)

1. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-Analysis of prospective studies. Inflamm Bowel Dis. 2012;18:1894-1899.
2. Lobaton T, Rodriguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis. 2013;19:1034-1042.
3. Guardiola J, Lobaton T, Rodriguez-Alonso L, et al. Fecal level of calprotectin Identifies Histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014; 12:1865-1870.
4. Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104: 673-678. 19262524.
5. Rogler G, Aldeguer X, Kruis W, et al. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohns Colitis. 2013;7:670-677.
6. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14: 40-46.
7. Molander P, Bjorkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF alpha blocking agents. Inflamm Bowel Dis. 2012;18:2011-2017.
8. De Vos M, Dewit O, D'Haens G, et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF na've patients with ulcerative colitis. J Crohns Colitis. 2012;6:557-562.
9. Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15:1851-1858.
10. Wagner M, Peterson CG, Ridefelt P, et al. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14:5584-5589.
11. Sipponen T, Bjorkesten CG, Farkkila M, et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol. 2010;45:325-331.
12. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793-798.
13. Moum B, Jahnsen J, Bernklev T. Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis. 2010;16:1091-1092.
14. Naismith GD, Smith LA, Barry SJ, et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther. 2013;37:613-621.
15. Lasson A, Stotzer PO, Ohman L, et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9:26-32.
16. Kolho KL, Alfthan H, Hamalainen E. Effect of bowel cleansing for colonoscopy on fecal calprotectin levels in pediatric patients. J Pediatr Gastroenterol Nutr. 2012;55:751-753.
17. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32.
18. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5A-36A.
19. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-Aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
20. Coorevits L, Baert FJ, Vanpoucke HJ. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med. 2013;51:825-831.
21. Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue rapid test for faecal calprotectin. Ann Clin Biochem. 2012;49(pt 1):55-58.
22. Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. J Crohns Colitis. 2013;7: e641-651.
23. Joshi S, Lewis SJ, Creanor S, et al. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem. 2010;47(pt 3):259-263.
24. Poullis A, Foster R, Shetty A, et al. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2004;13:279-284.
25. Dobrzanski C, Pedersen N, Voxen Hansen V, et al. Is there a diurnal variation in faecal calprotectin in inflammatory bowel disease patients?. United European Gastroenterol J. 2013;1(suppl 1):A209.
26. Labaere D, Smismans A, Van Olmen A, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J. 2014;2:30-37.
27. Burri E, Manz M, Rothen C, et al. Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease inpatients with abdominal discomfort. Clin Chim Acta. 2013;416:41-47.